Evaluation of a Drug Combination in Patients with Cutaneous T-cell Lymphomas (CTCL)

The primary objective of this study is the evaluation of therapeutic outcomes in patients diagnosed with cutaneous T-cell lymphoma. This investigation is clinically significant for determining the management efficacy within this specific hematologic malignancy. There are no secondary objectives reported.

The sponsor did not provide information regarding the total number of participants. The study population consists of patients diagnosed with cutaneous T-cell lymphoma. The cohort includes both male and female individuals within the age ranges of 3 to 5 years.

This Phase 1 clinical trial utilizes a randomized, double-blind, controlled design to evaluate interventions for cutaneous T-cell lymphoma. The study procedures involve a sequence of scheduled assessments, beginning with a screening visit to determine eligibility. Subsequent follow-up visits are conducted to monitor clinical progress and safety. The protocol concludes with an end-of-study visit. The total duration of the trial is estimated to span from November 2025 to August 2028. Participant involvement may be subject to early termination based on specific clinical criteria or safety protocols defined within the study framework.

The assessment of efficacy in this phase 1 clinical trial for cutaneous T-cell lymphoma is not specified.